Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026GlobeNewsWire · 5 days ago
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis TranscriptSeeking Alpha · Sep 30, 2026
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026GlobeNewsWire · Sep 30, 2026
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to BrokeragesDefense World · Sep 28, 2026
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 9, 2026
Jade Biosciences to Participate in Upcoming ConferencesGlobeNewsWire · Sep 1, 2026Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.64 | -$0.76 | Miss |
| May 7, 2026 | -$0.52 | -$0.57 | Miss |
| Mar 6, 2026 | -$0.45 | -$0.45 | Beat |
| Nov 14, 2025 | -$0.57 | -$0.48 | Beat |
| Aug 14, 2025 | -$0.43 | -$0.86 | Miss |
| Apr 25, 2025 | -$6.03 | -$12.10 | Miss |